Cuts to CV Sales Force

Quote
anonymous said:
"use PRISM".
Thanks. I needed a laugh today.
Even the dunderheads in New Jersey know better.
Click to expand...
The Repatha data is pretty accurate. It’s Buy and Bill data Novartis can’t seem to understand. The sale happens when the facility “Buys” it, so all we need is that 867 data to measure sales. Of course, in true Novartis fashion, they are determined to make it more complicated than it is.
Of course the ASOC data makes it much more complicated. That’s why it’s been foolish from the beginning to encourage accounts to use an ASOC. We should all be focusing on Buy and Bill, either in privately owned offices or in system owned offices, but not sending to ASOCs where we have no control over patient experience, their reporting data, etc. But from the beginning Novartis has marketed heavily toward ASOCs. We all had to teach offices what in the heck those were! Now we gnash our teeth about not being able to get accurate data from them. Big shocker.
 






If only that easy. Telling an office they have to buy and bill so Novartis can get accurate data to pay their sales reps accurately is not the offices problem. They should use whatever route best for their practice. The data from the ASOC in my area is pretty accurate. The BS part of it is Novartis waiting for claims data so they can get it drilled down to the Dr. in the hope one day will have territory goals. Too long of a delay for the data. As stated, 867 data should be all that’s needed. Novartis needs to figure out a better way to incentivize reps for this product. All the resources spent on trying to figure out the data that no one trusts is crazy. In the mean time, you have reps enjoying Presidents Club and large bonus’ that haven't moved anything. Not motivating Novartis. Get it together.
 






anonymous said:
If only that easy. Telling an office they have to buy and bill so Novartis can get accurate data to pay their sales reps accurately is not the offices problem. They should use whatever route best for their practice. The data from the ASOC in my area is pretty accurate. The BS part of it is Novartis waiting for claims data so they can get it drilled down to the Dr. in the hope one day will have territory goals. Too long of a delay for the data. As stated, 867 data should be all that’s needed. Novartis needs to figure out a better way to incentivize reps for this product. All the resources spent on trying to figure out the data that no one trusts is crazy. In the mean time, you have reps enjoying Presidents Club and large bonus’ that haven't moved anything. Not motivating Novartis. Get it together.
Click to expand...
Agree with all of this except you don’t tell offices they have to buy and bill any more than you tell them they have to use a product. You sell them on the benefits and if they aren’t an office that can do that, you work within their system to find a way. If they truly don’t do any buy and bill and you can’t sell them, you move on. That’s just how it’s done with every other buy and bill product. It’s sales.
And you are exactly right. A bunch of stupid pharma execs who can’t understand buy and bill isn’t pharma and you will never have accurate provider level data. All we need is the “buy” part of the buy and bill market, and we have that….except when it comes to ASOCs. If they reduce headcount, they could even alleviate the problem of splitting up ASOC credit, unfortunately. I’ll never understand why the fools at Novartis think we should get paid on the “bill” part of buy and bill. No other company does that because they understand it’s getting the buyer to buy it that is actually the sale.
 






Agree. What the purchaser does with the product after buying it isn't our problem. Credit should should strictly be based on the buy. I was told by manager the only reason Novartis cares about the bill/claims data is so they can get accurate provider level data from ASOC for incentive and goaling. So stupid.
 






anonymous said:
Agree. What the purchaser does with the product after buying it isn't our problem. Credit should should strictly be based on the buy. I was told by manager the only reason Novartis cares about the bill/claims data is so they can get accurate provider level data from ASOC for incentive and goaling. So stupid.
Click to expand...
Also, how pissed are we going to be when we have sold 10 units to an office and the claims data they buy can only track 7 of them?
 












Are you saying even if office is buying and billing, Novartis is only giving you credit on the claims data? I thought only ASOCs were held to that and B&B offices paid on the buying since Novartis knew where it was going. That is terrible the claims data doesn’t match. Really unmotivating.
 






anonymous said:
Are you saying even if office is buying and billing, Novartis is only giving you credit on the claims data? I thought only ASOCs were held to that and B&B offices paid on the buying since Novartis knew where it was going. That is terrible the claims data doesn’t match. Really unmotivating.
Click to expand...
That’s what we are hearing is going to be going forward when we get individual goals. Novartis is managing buy and bill like a pharma product so they can massage the numbers with their usual smoke and mirrors tactics to ensure we don’t get paid like buy and bill reps. They will stop letting us have access to that 867 data too so we don’t go comparing what we actually sold to what they decide to pay us on. This is the kind of bullshit we have come to expect. Remember this when your next GLINT survey asks you if Novartis provides “clarity.”
 






anonymous said:
That’s what we are hearing is going to be going forward when we get individual goals. Novartis is managing buy and bill like a pharma product so they can massage the numbers with their usual smoke and mirrors tactics to ensure we don’t get paid like buy and bill reps. They will stop letting us have access to that 867 data too so we don’t go comparing what we actually sold to what they decide to pay us on. This is the kind of bullshit we have come to expect. Remember this when your next GLINT survey asks you if Novartis provides “clarity.”
Click to expand...
When you say they will stop letting reps have access to the 867 data, what do you mean? They don't send it directly to the reps now and, as far as I know, they never have. I also wouldn't worry about territory goals happening anytime soon, if ever.
 






They prob meant the manager wont have access to the 867. Our manager shares the info on it all the time. You watch, Novartis will push territory level goaling sooner than you think. They won’t be ready for it, it will be a mess, most will get screwed, a few lucky. Waiting for claim data to come in on a b&b office is ridiculous. Getting real hard to leave house and talk about this product.
 






Let’s face it, it’s not a commission based sales incentivized job anymore. Still a job, not a bad job, but not really a sales job because they don’t pay us like sales people.
 






anonymous said:
Let’s face it, it’s not a commission based sales incentivized job anymore. Still a job, not a bad job, but not really a sales job because they don’t pay us like sales people.
Click to expand...
This is accurate. All incentive was destroyed when they decided that territory based goaling wasn't important.
It is sad and bizarre, but it is what senior management wants. I hope it served them well.
 






















































Top Bottom
Back
Quote